

Yu-Qing Liu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4846561/publications.pdf>

Version: 2024-02-01

18
papers

724
citations

623574

14
h-index

887953

17
g-index

18
all docs

18
docs citations

18
times ranked

832
citing authors

#	ARTICLE	IF	CITATIONS
1	m6A RNA methylation regulators contribute to malignant progression and have clinical prognostic impact in gliomas. <i>Aging</i> , 2019, 11, 1204-1225.	1.4	209
2	Systematically characterize the clinical and biological significances of 1p19q genes in 1p/19q non-codeletion glioma. <i>Carcinogenesis</i> , 2019, 40, 1229-1239.	1.3	60
3	Prognostic power of a lipid metabolism gene panel for diffuse gliomas. <i>Journal of Cellular and Molecular Medicine</i> , 2019, 23, 7741-7748.	1.6	59
4	The molecular characteristics of spinal cord gliomas with or without H3 K27M mutation. <i>Acta Neuropathologica Communications</i> , 2020, 8, 40.	2.4	51
5	Classification of diffuse lower-grade glioma based on immunological profiling. <i>Molecular Oncology</i> , 2020, 14, 2081-2095.	2.1	48
6	Combinations of four or more CpGs methylation present equivalent predictive value for MGMT expression and temozolomide therapeutic prognosis in gliomas. <i>CNS Neuroscience and Therapeutics</i> , 2019, 25, 314-322.	1.9	42
7	Molecular subtyping reveals immune alterations in <i>IDH</i> wild-type lower-grade diffuse glioma. <i>Journal of Pathology</i> , 2020, 251, 272-283.	2.1	42
8	A novel analytical model of MGMT methylation pyrosequencing offers improved predictive performance in patients with gliomas. <i>Modern Pathology</i> , 2019, 32, 4-15.	2.9	41
9	Amino acid metabolism-related gene expression-based risk signature can better predict overall survival for glioma. <i>Cancer Science</i> , 2019, 110, 321-333.	1.7	39
10	Systematically profiling the expression of eIF3 subunits in glioma reveals the expression of eIF3i has prognostic value in IDH-mutant lower grade glioma. <i>Cancer Cell International</i> , 2019, 19, 155.	1.8	27
11	Peripheral blood test provides a practical method for glioma evaluation and prognosis prediction. <i>CNS Neuroscience and Therapeutics</i> , 2019, 25, 876-883.	1.9	27
12	A Novel DNA Methylation-Based Signature Can Predict the Responses of MGMT Promoter Unmethylated Glioblastomas to Temozolomide. <i>Frontiers in Genetics</i> , 2019, 10, 910.	1.1	22
13	RNA processing genes characterize RNA splicing and further stratify lower-grade glioma. <i>JCI Insight</i> , 2019, 5, .	2.3	20
14	Gene Expression Profiling Stratifies IDH-Wildtype Glioblastoma With Distinct Prognoses. <i>Frontiers in Oncology</i> , 2019, 9, 1433.	1.3	16
15	Phosphohistone H3 (pHH3) is a prognostic and epithelial to mesenchymal transition marker in diffuse gliomas. <i>Oncotarget</i> , 2016, 7, 45005-45014.	0.8	10
16	Recurrent PTPRZ1-MET fusion and a high occurrence rate of MET exon 14 skipping in brain metastases. <i>Cancer Science</i> , 2022, 113, 796-801.	1.7	7
17	Characterization and prognostic significance of alternative splicing events in lower-grade diffuse gliomas. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 13171-13180.	1.6	4
18	ð”ð•ð’ðšð† ðð;ðŸð•ðšðçð`ðžðŸðçð`ðœð†ð—ðð ð†ð‡ ð’ð’ð’sð•ððð`ðŸð†ðð‡ðð“ð†ðšðð`ðŸ ð†ðð;ððð‡ðœðððçð†ð’		